Drugs / LAS41004 IMP4
last change Jun 2014 re-read 3 minutes ago

LAS41004 IMP4

Developed for
psoriasis
Investigated by
Almirall, S.A. · proDERM GmbH

Trials 1

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02111499 Mar → May 2014 psoriasis Almirall, S.A. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LAS41004 IMP4 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02111499 ↗
Route Topical “daily topical application” NCT02111499 ↗